{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T21:58:16Z","timestamp":1761170296205,"version":"build-2065373602"},"reference-count":22,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,10,9]],"date-time":"2016-10-09T00:00:00Z","timestamp":1475971200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hellenic Journal of Cardiology"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.hjc.2016.11.022","type":"journal-article","created":{"date-parts":[[2016,11,12]],"date-time":"2016-11-12T18:30:36Z","timestamp":1478975436000},"page":"215-219","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Bevacizumab increases the incidence of cardiovascular events in patients with metastatic breast or colorectal cancer"],"prefix":"10.1016","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4822-4524","authenticated-orcid":false,"given":"Ioannis","family":"Kapelakis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantinos","family":"Toutouzas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Drakopoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Archontoula","family":"Michelongona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flora","family":"Zagouri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aristotle","family":"Mpamias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paraskevi","family":"Pliatsika","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meletios-Athanasios","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christodoulos","family":"Stefanadis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios","family":"Tousoulis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.hjc.2016.11.022_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/1097-0177(2000)9999:9999<::AID-DVDY1087>3.0.CO;2-2","article-title":"The role of FGF and VEGF in angioblast induction and migration during vascular development","volume":"220","year":"2001","journal-title":"Dev Dyn"},{"issue":"21","key":"10.1016\/j.hjc.2016.11.022_bib2","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","article-title":"Tumor angiogenesis: therapeutic implications","volume":"285","author":"Folkman","year":"1971","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.hjc.2016.11.022_bib3","first-page":"587","article-title":"The prognostic significance of angiogenesis in epithelial ovarian carcinoma","volume":"5","author":"Alvarez","year":"1999","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.hjc.2016.11.022_bib4","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1146\/annurev.cb.11.110195.000445","volume":"11","author":"Risau","year":"1995","journal-title":"Vasculogenesis. Annu Rev Cell Dev Biol."},{"key":"10.1016\/j.hjc.2016.11.022_bib5","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1200\/JCO.2003.10.066","article-title":"Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)\/leucovorin (LV) with FU\/LV alone in patients with metastatic colorectal cancer","volume":"21","author":"Kabbinavar","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hjc.2016.11.022_bib6","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1200\/JCO.2006.09.6305","article-title":"Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group study E3200","volume":"25","author":"Giantonio","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hjc.2016.11.022_bib7","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1200\/JCO.2007.14.5466","article-title":"Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil","volume":"27","author":"Reck","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hjc.2016.11.022_bib8","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel\u2013carboplatin alone or with bevacizumab for non\u2013small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hjc.2016.11.022_bib9","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/j.clinthera.2006.11.015","article-title":"Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies","volume":"28","author":"Shih","year":"2006","journal-title":"Clin Ther"},{"issue":"suppl. 3","key":"10.1016\/j.hjc.2016.11.022_bib10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1159\/000088481","article-title":"Managing patients treated with bevacizumab combination therapy","volume":"69","author":"Gordon","year":"2005","journal-title":"Oncology"},{"issue":"15 suppl.","key":"10.1016\/j.hjc.2016.11.022_bib11","doi-asserted-by":"crossref","first-page":"4103","DOI":"10.1200\/jco.2008.26.15_suppl.4103","article-title":"The safety of long-term bevacizumab use: Results from the BRiTE observational cohort study (OCS)","volume":"26","author":"Purdie","year":"2008","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1016\/j.hjc.2016.11.022_bib12","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1093\/jnci\/djm086","article-title":"Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab","volume":"99","author":"Scappacticci","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.hjc.2016.11.022_bib13","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.1200\/JCO.2005.10.017","article-title":"Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer","volume":"23","author":"Hurwitz","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hjc.2016.11.022_bib14","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1200\/JCO.2005.05.098","article-title":"Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer","volume":"23","author":"Miller","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hjc.2016.11.022_bib15","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1200\/JCO.2004.11.022","article-title":"Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-lung cancer","volume":"22","author":"Johnson","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hjc.2016.11.022_bib16","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1161\/01.CIR.0000133187.74800.B9","article-title":"Cardiovascular complications of cancer therapy: Diagnosis, pathogenesis and management","volume":"109","author":"Yeh","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.hjc.2016.11.022_bib17","doi-asserted-by":"crossref","first-page":"7135","DOI":"10.1200\/JCO.2005.16.139","article-title":"Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas","volume":"23","author":"D'Adamo","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hjc.2016.11.022_bib18","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1158\/1078-0432.CCR-03-0627","article-title":"Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab","volume":"10","author":"Karp","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hjc.2016.11.022_bib19","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/0046-8177(95)90148-5","article-title":"Intimal neovascularisation in human coronary atherosclerosis","volume":"26","author":"Kumamoto","year":"1995","journal-title":"Hum Pathol"},{"key":"10.1016\/j.hjc.2016.11.022_bib20","first-page":"11","article-title":"Inhibition of angiogenesis: common theme for cancer and atheromatosis?","volume":"47","author":"Bamias","year":"2006","journal-title":"Hellenic J Cardiol"},{"key":"10.1016\/j.hjc.2016.11.022_bib21","first-page":"129","article-title":"Advances in vulnerable plaque detection and treatment: how far have we gone?","volume":"47","author":"Toutouzas","year":"2006","journal-title":"Hellenic J Cardiol"},{"issue":"2","key":"10.1016\/j.hjc.2016.11.022_bib22","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.atherosclerosis.2006.12.034","article-title":"Inhibition of plaque neovascularization and intimal hyperplasia by specific targeting vascular endothelial growth factor with bevacizumab-eluting stent: an experimental study","volume":"195","author":"Stefanadis","year":"2007","journal-title":"Atherosclerosis"}],"container-title":["Hellenic Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1109966616302366?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1109966616302366?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:11:10Z","timestamp":1761099070000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1109966616302366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S1109966616302366"],"URL":"https:\/\/doi.org\/10.1016\/j.hjc.2016.11.022","relation":{},"ISSN":["1109-9666"],"issn-type":[{"type":"print","value":"1109-9666"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bevacizumab increases the incidence of cardiovascular events in patients with metastatic breast or colorectal cancer","name":"articletitle","label":"Article Title"},{"value":"Hellenic Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hjc.2016.11.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Hellenic Society of Cardiology. Publishing services by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}